1453005
USP
Naloxone
United States Pharmacopeia (USP) Reference Standard
Synonym(s):
(5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propen-1-yl)morphinan-6-one
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C19H21NO4
CAS Number:
Molecular Weight:
327.37
UNSPSC Code:
41116107
Recommended Products
grade
pharmaceutical primary standard
API family
naloxone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
InChI
1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
InChI key
UZHSEJADLWPNLE-GRGSLBFTSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Naloxone USP Reference standard for use in specified quality tests and assays.
Also used to prepare standard, system suitability, and Sensitivity solution for the assay, identification, impurity analysis, and performance test by liquid chromatography coupled with UV detector in accordance with the given below monographs of united states pharmacopeia (USP) :
Also used to prepare standard, system suitability, and Sensitivity solution for the assay, identification, impurity analysis, and performance test by liquid chromatography coupled with UV detector in accordance with the given below monographs of united states pharmacopeia (USP) :
- Naloxone Hydrochloride
- Buprenorphine and Naloxone Sublingual Tablets
- Pentazocine and Naloxone Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
related product
Product No.
Description
Pricing
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Nina Eriksen et al.
International journal of stroke : official journal of the International Stroke Society, 9(6), 802-810 (2012-08-30)
Strokes have both ischemic and hemorrhagic components, but most studies of experimental stroke only address the ischemic component. This is likely because investigations of hemorrhagic transformation are hindered by the lack of methods based on unbiased principles for volume estimation.
Marco Lanza et al.
British journal of pharmacology, 171(15), 3693-3701 (2014-04-25)
CR4056 is a novel imidazoline-2 (I2 ) ligand exhibiting potent analgesic activity in animal models of pain. In this study, we investigated the effects of CR4056 in a well-established model of postoperative pain where rats develop hyperalgesia in the injured
Daisuke Yamada et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(8), 1852-1860 (2014-02-13)
Although the underlying mechanism remains unknown, several studies have suggested benefits of n-3 long-chain polyunsaturated fatty acid (PUFA) for patients with anxiety disorders. Elevated fear is thought to contribute to the pathogenesis of particular anxiety disorders. The aim of the
Prabhat Singh et al.
Psychopharmacology, 232(2), 465-475 (2014-07-26)
Opiate exposure for longer duration develops state of dependence in humans and animals, which is revealed by signs and symptoms of withdrawal precipitated by opioid receptor antagonists. The sudden withdrawal of opioids produces a withdrawal syndrome in opioid-dependent subjects. Insulin
Ana M Torres-Guzman et al.
Arthritis research & therapy, 16(2), R64-R64 (2014-03-13)
Clinical and preclinical studies have shown that supplementation with ω-3 polyunsaturated fatty acids (ω-3 PUFAs) reduce joint destruction and inflammation present in rheumatoid arthritis (RA). However, the effects of individual ω-3 PUFAs on chronic arthritic pain have not been evaluated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service